 I think the FDA is listening. There's no doubt through their workshops they're hearing from patients and they're hearing a voice that's more clear and loud now than ever before, which is a very good thing. I think translating that, though, into action in terms of how to bring new therapies forward is where we're somewhat stalled at this point. And that's the connection that we hope to make using these new measures or new endpoints. Mm-hmm.